Cardiometabolic comorbidities

There are 20 papers on cardiometabolic comorbidities in aging research: 15 observational studies in people, 5 reviews. The newest story, Nov 9, 2026: “Diabetes drugs linked to fewer deaths in young adults”.

Disease

20 papers study it146 more mention it7 findings

44 new papers in 30 daysSee all 166 papers on cardiometabolic comorbidities

“obesity significantly increased the risk of DM (HR 4.10, 95%CI 3.83-4.32), CMC (HR 2.36, 95%CI 2.29-2.47)”
Prepregnancy obesity, adverse pregnancy outcome patterns, and early postpartum cardiometabolic risk: a mediation analysis identified by latent class analysisESC Congress 2026 abstract2026doi:10.1093/eurheartj/ehag785.3912
  • Humans15

Effects

1

Neutrophil count

upin humans1

1 study
  1. Cardiometabolic comorbidities are linked with higher neutrophil count in humans (4.1 × 109/L vs 3.83 × 109/L).

    Humansbloodfemales

More on Neutrophil count

Associations

6

Prepregnancy obesity

upin humans1HR 2.36

1 study
  1. Prepregnancy obesity is linked with a higher risk of cardiometabolic comorbidities in humans (Prepregnancy obesity compared with normal weight) (HR 2.36, 95% CI 2.29–2.47).

    HumansPrepregnancy obesity compared with normal weightBMI≥28 kg/m2Median follow-up of 5.8 yearsn = 555,591

More on Prepregnancy obesity

Hidradenitis suppurativa

upin humans1

1 study
  1. Hidradenitis suppurativa is associated with cardiometabolic comorbidities in humans.

    Humansindex date to GLP-1RA initiation

More on Hidradenitis suppurativa

Asian americans

mixedin humans1

1 study
  1. Asian americans are associated with cardiometabolic comorbidities in humans (Asian Americans with chronic hepatitis B) (61.93% had at least one cardiometabolic condition; 28.90% had two or more).

    HumansAsian Americans with chronic hepatitis Bn = 436

More on Asian americans

Treatment discontinuation

downin humans1

1 study
  1. Cardiometabolic comorbidities are linked with a lower risk of treatment discontinuation in humans (people with obesity, comparing subgroups with T2D, CVD or MASLD to the obesity-only group) (median treatment duration 68 days longer in Group 4 than Group 1; 12-month discontinuation 47% vs 55%).

    Humanspeople with obesity, comparing subgroups with T2D, CVD or MASLD to the obesity-only groupn = 201,391

microRNA

upin humans1

1 study
  1. Cardiometabolic comorbidities are associated with microRNA in CoRIS cohort.

    Humansin CoRIS cohortPBMC

More on microRNA

Airway-predominant COPD

upin humans1

1 study
  1. Airway-predominant COPD is associated with cardiometabolic comorbidities in humans (airway-predominant COPD).

    Reviewairway-predominant COPD

More on Airway-predominant COPD

Latest

Dec 2025: 4Jan 2026: 5Feb 2026: 8Mar 2026: 13Apr 2026: 7May 2026: 4Jun 2026: 6Jul 2026: 8Aug 2026: 9Sep 2026: 7Oct 2026: 30Nov 2026: 21122 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Diabetes drugs linked to fewer deaths in young adults

Among young adults with type 2 diabetes, semaglutide users had a one-year relative risk of death of 0.416 compared with metformin users.Among young adults with type 2 diabetes, semaglutide users had a one-year relative risk of death of 0.416 compared with metformin users.

Cohort studyType 2 diabetes
Frontiers in Public Health

Knee osteoarthritis linked to higher osteoporosis risk

Osteoporosis developed in 5.2% of participants with knee osteoarthritis versus 3.9% without it over a median 10 years of follow-up.Osteoporosis developed in 5.2% of participants with knee osteoarthritis versus 3.9% without it over a median 10 years of follow-up.

Cohort · 406,810 peopleKnee osteoarthritis
medRxiv

Sleep duration and breathing linked separately to heart risk

After adjustment, short and long sleep were associated with heart-attack odds 1.24 and 1.30 times those of the reference group, respectively.After adjustment, short and long sleep were associated with heart-attack odds 1.24 and 1.30 times those of the reference group, respectively.

Preprint: study in peoplePopulations

See all 166 papers on cardiometabolic comorbidities